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Abstract
Background: The efficacy and safety of direct-acting antiviral agents (DAAs) were evaluated in a cohort of prospectively
enrolled patients with hepatitis C virus (HCV)-related mixed cryoglobulinaemia (MC), an immune complex-mediated
vasculitis of small and medium vessels in which the pathogenetic role of HCV has been clearly established.
Methods: Twenty-two patients received DAAs. Clinical and laboratory features were recorded at baseline, every
4 weeks until the end of treatment (EoT), and 12 weeks afterwards. Primary efficacy endpoints were (a) sustained
virological response 12 weeks after therapy completion (SVR12), (b) regression of symptomatology (clinical
response) and (c) cryoglobulin disappearance or cryocrit reduction ≥50% (immunological response). Complete
response (CR) was defined as the occurrence of all three primary endpoints; partial response (PR) was defined as
the occurrence of SVR12, with or without either immunological or clinical response; and no response was defined
as missing the achievement of all three endpoints.
Results: All patients reached SVR12. Compared with basal values, mean cryocrit values were significantly decreased at
EoT and SVR12. A significant reduction of alanine transaminase and a parallel increase of complement component C4
levels were also detected. Rheumatoid factor activity was significantly reduced at EoT but not at SVR12. At SVR12, a CR
was established in 14 patients (63.7%) and a PR in 8 patients (36.3%). In one patient with small lymphocytic lymphoma,
the tumour progressed despite viral clearance. Mild adverse events were recorded in nine patients (40.9%).
Conclusions: The response rates induced by the use of DAAs in patients with MC were remarkably higher than
those previously achieved with pegylated interferon-α/ribavirin, with or without rituximab. A much longer
follow-up is desirable to achieve useful information in terms of persistent viral clearance and clinical response.
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Background
Hepatitis C virus (HCV) is a major cause of chronic liver
disease that can potentially progress to cirrhosis and hepa-
tocellular carcinoma (HCC) [1–3]. It has been estimated
that about 130 million to 150 million people worldwide
have HCV infection and that HCV causes about 500,000
deaths each year [4]. In addition to liver damage, HCV in-
fection is associated with several extrahepatic disorders
[5]; among them, the striking association between HCV
infection and mixed cryoglobulinaemia (MC), an immune
complex-mediated vasculitis of small and medium vessels,
has been clearly established [6, 7]. On the basis of B-cell
clonal expansion that can be detected in the majority of
patients, MC can also be considered a low-grade, indolent
lymphoproliferative disorder [8].
Clinically, MC is characterised by the classic Meltzer’s
triad of symptoms (purpura, weakness and arthralgia).
The clinical spectrum of MC is quite variable, however,
ranging from skin lesions, including recurrent purpuric
eruptions, leg dyschromatosis and torpid ulcers, to periph-
eral neuropathy and renal damage. In a minority of
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patients, multi-organ involvement may result in life-
threatening conditions [9, 10]. In our experience, com-
pared with patients with chronic HCV infection without
cryoglobulinaemia, HCV-positive patients with MC ex-
hibit a lower rate of liver fibrosis and a lower cumulative
probability of developing cirrhosis and HCC, but a more
frequent occurrence of renal failure, neurologic impair-
ment and B-cell non-Hodgkin lymphoma (B-NHL). Even
so, the 15-year survival rates in these groups have been
found to be roughly similar [11].
The therapeutic approach to MC has conventionally
been based on the use of steroids and immunosuppressive
drugs. Interferon (IFN)-based treatment was introduced
in 1987, before the identification of HCV as the major
etiologic factor [12, 13]. Subsequently, the antiviral
combination of pegylated interferon-α plus ribavirin
(pIFN-α + RBV) was employed to obtain a sustained
virological response (SVR), and for many years, this
combination has been considered the standard of care
for the treatment of chronic HCV infection, capable of
inducing SVR and clinical remission of vasculitis in
about 78% of patients with MC [14, 15]. A multicentre,
open-label study showed viral response rates ranging
from 36% to 64% according to viral genotype and a clin-
ical response in 88% of the patients [16]. The association
of rituximab (RTX), an anti-CD20 monoclonal antibody
aimed at inducing an effective B-cell depletion, resulted in
further benefits, both in patients refractory to antiviral
therapy [17, 18] and in those previously untreated [19]. In
our experience, the addition of RTX to the pIFN-α + RBV
combination has resulted in a 33% complete response
(CR) (i.e., virological, immunological and molecular re-
sponse) [19].
However, the efficacy of therapy in terms of viral clear-
ance has remained unsatisfactory and is burdened with
remarkable side effects. The use of first-generation prote-
ase inhibitors, such as boceprevir or telaprevir, associated
with pIFN-α + RBV in a triple-combination therapeutic
regimen resulted in significantly higher response rates in
patients with chronic HCV infection without and with
MC. Serious adverse events were recorded in almost 50%
of patients, however [20].
The introduction of all-oral, direct-acting antiviral
agents (DAAs) has dramatically changed the treatment
of chronic HCV and consequently the prognosis of these
patients. According to the viral molecular target, DAAs
include inhibitors of non-structural proteins NS3/NS4
(simeprevir, paritaprevir and grazoprevir), NS5A (ledipasvir
[LDV], daclatasvir [DCV], ombitasvir, elbasvir and velpa-
tasvir) and NS5B (sofosbuvir [SOF] and dasabuvir) that are
already available in Italy, except elbasvir, grazoprevir and
velpatasvir, for which approval is pending. These drugs
have been shown to be capable of eradicating the infection
in over 90% of patients with chronic HCV, with limited
variations related to viral genotype [21]. An additional ad-
vantage of DAAs is the possibility of avoiding IFN-related
side effects. However, owing to the high costs of these
drugs, it has been necessary to fix priority criteria among
patients to be treated. Both the American and the Euro-
pean associations for the study of liver diseases, as well as
the Italian Medicines Agency (AIFA), have established that
extrahepatic manifestations of HCV infection, such as
cryoglobulinaemic vasculitis and lymphoproliferative
disorders, should be recognised as priority indications
for treatment with DAAs [22, 23].
So far, only a few papers have been published on the
efficacy and safety of the use of DAAs in patients with
MC. Saadoun et al. [24] reported a 74% rate of sustained
virological response 12 weeks after therapy completion
(SVR12) and an 87.5% clinical response rate in 24 patients
with HCV-related MC treated with an SOF plus RBV
combination. In another study, carried out with 12 pa-
tients with MC (7 of whom had renal involvement)
treated with SOF-based regimens, the SVR12 rate was
83% and was associated with improvement in serum
creatinine and reduction in proteinuria in patients with
glomerulonephritis. In addition, an overall reduction or
disappearance of cryoglobulins was recorded in 89% of
the patients [25]. Mention should also be made of a
prospective double-centre (Florence/Rome) study of a
cohort of 44 consecutive patients with HCV-associated
MC, 2 of whom had evolved into an indolent NHL with
monoclonal B-cell lymphocytosis. Following guideline-
tailored therapy with DAAs, an SVR was demonstrated
12 and 24 weeks post-treatment in parallel with clinical
response in all patients. A striking reduction in the
mean cryocrit value was revealed at SVR12, and an even
greater reduction was observed for sustained virological
response 24 weeks after therapy completion (SVR24). A
partial vasculitis response and a roughly 50% reduction
of cryocrit were detected in the two patients with
lymphoma. Adverse events were rather frequent but
usually mild [26]. More recently, Bonacci et al. [27] re-
ported a large prospective study of 64 cryoglobulinae-
mic patients with HCV infection, divided into those
with symptomatic (55% of cases) cryoglobulinaemia
and those with asymptomatic cryoglobulinaemia (45%
of cases). Sixteen percent of the patients received an
IFN-based DAA combination, whereas IFN-free regi-
mens were administered to the remaining patients.
Overall, 94% of patients showed SVR12, and 71%
achieved a clinical CR. In 10 of 13 patients, concomi-
tant immunosuppressive therapy was reduced or with-
drawn. Forty-eight percent of patients achieved an
immunological response, defined as disappearance of
circulating cryoglobulins and normalisation of comple-
ment and/or rheumatoid factor (RF). However, despite
SVR12 in 52% of patients, cryoglobulins or complement
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consumption or RF activity persisted, a low baseline
cryocrit level being the only factor associated with an
immunological CR.
We report the results of our single-centre, prospective
study of a cohort of patients with MC whose main features
can be summarised as follows: (a) unresponsiveness to or
relapse after the previous standard-of-care treatment
consisting of pIFN-α + RBV combination, or previously
untreated patients; (b) the assignment to receive variable
combinations of DAAs according to the guidelines of
the AIFA eligibility criteria; and (c) a post-treatment evalu-
ation at weeks 12 and 24, with a prolonged follow-up until
12 months in some cases.
Methods
Patients
Twenty-two consecutive HCV-positive patients with MC
were enrolled in this study, with the aim being to assess
both the efficacy and the safety of all-oral, IFN-free
DAAs. Thirteen patients were non-responsive to or re-
lapsed after previous pIFN-α + RBV combination therapy,
whereas the remaining nine patients were treatment-
naïve. Written informed consent was obtained from all
patients. Because treatments were administered on-label,
no approval by the ethics committee was required, and
the study was conducted according to the principles of the
Declaration of Helsinki.
Clinical and virological evaluation
All patients were thoroughly examined according to vali-
dated criteria reported elsewhere [28]. Clinical features
included the presence of purpura, fatigue and arthralgia,
associated or not with skin ulcers. Renal damage and/or
peripheral nervous system involvement were also looked
for. Circulating cryoglobulins were detected as previously
described [29–31] and immunochemically characterised
by immunofixation, and their amounts were quantified as
cryocrit (%). Serum HCV RNA levels were assessed using
the AmpliTaq real-time polymerase chain reaction system
with a detection threshold of 15 IU/ml (Roche Molecular
Systems Inc., Pleasanton, CA, USA), whereas HCV
genotyping was performed using the VERSANT HCV
genotype 2.0 assay (LiPA) (Siemens Healthcare Molecular
Diagnostics, Berkeley, CA, USA).
Treatment schedules
Patients admitted to treatment had previously been ex-
amined by transient elastography (FibroScan; Echosens,
Paris, France) for the assessment of liver fibrosis grade.
Antiviral therapy was prescribed according to the AIFA
eligibility criteria, HCV genotype, grade of liver fibrosis
and prior treatment experience. For patients with RBV
treatment, dose reduction was considered in accordance
with technical schedule. The following regimens were
employed: (a) daily SOF (400 mg) plus RBV (1000 to
1200 mg, depending on whether the patient’s body weight
was ≤75 or >75 kg); (b) ombitasvir/paritaprevir/ritonavir
(12.5 mg/75 mg/50 mg) plus dasabuvir (250 mg) (3D
combo) twice daily, with or without weight-based RBV; (c)
SOF/LDV (400 mg/90 mg) once daily; and (d) SOF
(400 mg) plus DCV (60 mg) (SOF/DCV) once daily.
Biochemical evaluation
In addition to clinical examination, baseline evaluation
included aspartate transaminase/alanine transaminase
(ALT) values, haemoglobin level, platelet count, RF activ-
ity, serum levels of C3 and C4 complement component
fractions, and serum protein electrophoresis. The same
parameters were evaluated every 4 weeks during treat-
ment and 12 weeks after therapy completion to establish
whether SVR12 had been achieved.
Endpoints
Primary efficacy endpoints were (a) SVR12 (virological
response), (b) regression of clinical manifestations of vas-
culitis (clinical response) and (c) cryocrit reduction by at
least 50% or disappearance of cryoglobulins (immuno-
logical response). CR was defined as the occurrence of all
primary endpoints, partial response (PR) as the occurrence
of SVR12 with either immunological or clinical response,
and no response (NR) as the lack of all criteria.
Statistical analyses
To assess the statistical power and significance of CR
proportion (π1), criterion power analysis was performed
using G*Power 3.1 (Heinrich Heine University, Düsseldorf,
Germany) with a one-tailed binomial test (one-sample
case), assuming as the constant proportion the frequency
of CR to pIFN-α + RBV therapy in patients with cryo-
globulinaemia (π0 = 0.33) [19]. Sensibility (statistical
power) was fixed at 0.80. This was a one-tailed test be-
cause we assumed a greater antiviral efficacy of DAAs
as compared with pIFN-α + RBV therapy. To evaluate
the frequencies and differences of virological and immuno-
logical responses, as well as C4 complement fraction, RF
and ALT level normalisation, continuous variables were
categorised as dichotomous variables and statistically ana-
lysed by cross-tabs and χ2 test.
Continuous variables were first subjected to descrip-
tive statistical analyses to verify the normality of data
(Kolmogorov-Smirnov test). The statistical significance
of variable changes across the study was assessed by a
general linear model (GLM) repeated measures analysis.
Three factors (baseline, end of treatment [EoT] and
SVR12 time points) and four variables (cryocrit, RF, C4
complement fraction and ALT levels) were taken into
consideration. HCV RNA serum levels were excluded
from the GLM because the test results for HCV were
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negative in all patients after treatment. The Huynh-Feldt
test and group comparisons by simple contrasts were
used for univariate repeated measures analysis of vari-
ance to evaluate EoT and SVR12 time point variations
against the baseline. Two-tailed α probability (p value),
estimation of the effect size in the sample (η2), and stat-
istical power were reported, with p < 0.05 being consid-
ered significant. Statistical analyses were performed by
using IBM SPSS Statistics version 20.0 software (IBM,
Armonk, NY, USA).
Results
Fourteen patients were treated with the SOF/RBV regimen
for 12–24 weeks according to viral genotype and fibrosis
stage, and seven patients with genotype 1 infection were
treated with such a regimen before the availability of more
effective combinations that all guidelines considered as op-
timal. Three patients received a 3D combo regimen, four
with SOF/LDV and one SOF/DCV combination. Thirteen
of twenty-two patients had experienced treatment failure
in previous IFN-based therapeutic regimens. No statisti-
cally significant relationship was found between previous
treatment failure and response to DAAs.
Table 1 summarises the main clinical, biochemical and
virological characteristics of the patients enrolled. The
subjects’ mean age was 66.9 years, ranging from 46 to
84, and the male/female ratio was 8/14. All patients were
viraemic with HCV RNA levels ranging from 2.1 to 7.7
logarithmic IU/ml. The mean cryocrit value was 1.8%,
ranging from 0.5% to 4%. ALT levels ranged from 13 to
668 IU/L (mean ± SD 104.8 ± 144.7), and C4 complement
fraction ranged from 0 to 24 mg/dl (mean ± SD 9.6 ± 7.3).
RF activity ranged from 0 to 530 IU/ml (mean ± SD
69.3 ± 119.1). Cryoglobulins were immunochemically
characterised as type 2 MC (monoclonal immunoglobu-
lin M [IgM]/polyclonal IgG) in 21 patients and as type
3 MC (polyclonal IgM/polyclonal IgG) in the remaining
1 patient.
Meltzer’s triad of symptoms (purpura, arthralgia and
weakness) was consistently present in all patients. Cryo-
globulinaemic glomerulonephritis was recorded in four
patients (18.2%) and severe peripheral neuropathy in
two patients (9.1%). Autoimmune haemolytic anaemia
and idiopathic thrombocytopenic purpura were diagnosed
in two patients each. In addition, four patients (18.2%)
showed a monoclonal IgG component (two with κ light
chains and two with λ light chains) on serum protein
electrophoresis, and three patients received a diagnosis
of NHL, one with stage 4 small lymphocytic lymphoma
(SLL) who received SOF/RBV therapy for 24 weeks
followed by four RTX infusions at 1-week intervals, one
with marginal zone B-NHL that extended to ocular ad-
nexa previously treated with pIFN-α + RBV + RTX, and
one with diffuse centrocytic B-NHL who had received
chemotherapy 2 years before that had resulted in CR.
Finally, two patients who had previously received a
diagnosis of HCC were treated with locoregional abla-
tion therapies with no evidence of recurrence on the
basis of contrast-enhanced ultrasound and computed
tomography, both before starting therapy and following
its completion. At FibroScan evaluation, 12 patients
showed advanced liver fibrosis (6 with F3 and 6 with F4
fibrosis and no signs of decompensation), whereas an
F1 or F2 score was recorded in the remaining 10
patients.
Four weeks after starting therapy, HCV RNA deter-
mination was found to be almost invariably below the
lower limit of detection. A rapid and progressive reduction
of ALT levels until normalisation was also observed. These
strikingly positive results were confirmed throughout the
length of treatment. Consequently, all patients reached an
EoT response and SVR12 (Fig. 1a) in step with persistent
Table 1 Baseline clinical, virologic and laboratory parameters of
22 patients with chronic hepatitis C virus infection with mixed
cryoglobulinaemia
Parameters Data
Age, years, mean ± SD (range) 66.9 ± 11.2 (46–84)
Female sex, n (%) 14 (63.6)
Serum HCV RNA, logarithmic IU/ml, mean ± SD 6.02 ± 1.2 (2.1–7.7)




Cryocrit, %, mean ± SD (range) 1.8 ± 1.3 (0.5–4)
Cryoglobulin type, n (%)
II 21 (95.4)
III 1 (4.6)
C3, mg/dl (n.v. 90–180) (mean ± SD) 93.4 ± 15.3 (51–118)
C4, mg/dl (n.v. 10–40) (mean ± SD) 9.6 ± 7.3 (0–24)
RF, IU/ml (n.v. 10–15) (mean ± SD) 69.3 ± 119.1 (0–530)
Clinical features, n (%)
Meltzer’s triad 22 (100)
Glomerulonephritis 4 (18.1)
Peripheral neuropathy 2 (9.1)
Liver involvement
ALT, IU/L (n.v. 12–78) (mean ± SD) 104.8 ± 144.7 (13–668)
Cirrhosis, n (%) 12 (54.5)
HCV-related tumours, n (%)
Hepatocellular carcinoma 2 (10)
Non-Hodgkin lymphoma 1 (5)
Small lymphocytic lymphoma 1 (5)
Abbreviations: ALT Alanine transaminase, C3 and C4 Complement components,
GT Genotype, HCV Hepatitis C virus, RF Rheumatoid factor, n.v. Normal values
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ALT normalisation (Fig. 1b). Interestingly, seven patients
with genotype 1 infection who were given suboptimal
SOF/RBV combination therapy also showed SVR12.
An immunological response was observed at EoT in
18 patients (81.8%). In 12 patients (54.5%), cryoglobulins
completely disappeared, whereas in 6 patients (27.3%), a
cryocrit reduction ≥50% of basal values was observed
(Fig. 2a). A less remarkable reduction in cryocrit was
calculated in two additional patients, and roughly un-
changed levels were observed in the remaining two pa-
tients. At the time of SVR12, an overall immunological
response was recorded in 17 patients (77.3%). More
precisely, cryoglobulins were undetectable in 13 of
them and were reduced to <50% of basal value in 4 pa-
tients (Fig. 2a). Conversely, cryoglobulins were unchanged
in three of the remaining five patients at SVR12, and two
patients had relapsed at EoT evaluation.
Additional immunological features also showed a re-
markable improvement. As shown in Fig. 2b, test results
for RF activity were negative in 12 patients at EoT (54.5%)
and in 11 patients at SVR12 (50%). In two patients, RF
levels were undetectable at EoT but were increased again
at SVR12, whereas in one patient the RF test result was
negative only at SVR12. Serum C4 levels increased to the
normal range in 10 patients at EoT (45.5%) and in 13 pa-
tients at SVR12 (59.1%) (Fig. 2c).
Compared with basal parameters, cryocrit values were
significantly decreased at EoT and SVR12 (p < 0.0001
and p = 0.001, respectively) (Table 2). The decrease in
ALT levels (p < 0.0001 and p < 0.0001, respectively) and
the normalisation of C4 levels (p = 0.003 and p = 0.002,
respectively) also reached statistical significance. Con-
versely, RF activity was found to be significantly reduced
at EoT but not at SVR12 (p = 0.003 and p = 0.083, re-
spectively). The results of univariate analysis were statis-
tically significant for all parameters. In addition,
considering the effect size value (η2), a remarkable effect
of therapy was observed for all biochemical parameters,
the effect being particularly prominent for cryocrit and
ALT levels (η2 = 0.470 and η2 = 0.572, respectively).
These results were confirmed by cross-tabs and χ2 tests,
in that the disappearance of cryoglobulins and ALT nor-
malisation were strongly influenced by therapy (Fig. 3).
In terms of clinical manifestations, we observed regres-
sion of Meltzer’s triad of symptoms (cryoglobulinaemic
glomerulonephritis and peripheral neuropathy), which ei-
ther were no longer present or were remarkably reduced in
20 patients (90.9%) and 16 patients (72.7%) at EoT and
SVR12, respectively. Two patients with peripheral neur-
opathy had only a partial benefit during antiviral treatment
and showed progressive deterioration after EoT. One pa-
tient with glomerulonephritis experienced a worsening of
renal function at the time of SVR12, but progression of
glomerulonephritis to end-stage kidney disease was not ob-
served. Another patient complained of persistent purpuric
rashes throughout the treatment and the follow-up period.
The patient with SLL treated with DAAs experience a
tumour progression that required chemotherapy with flu-
darabine and cyclophosphamide in addition to RTX. No
recurrence or disease progression was recorded in the two
patients with previously treated HCC.
According to the above-mentioned response criteria at
the time of EoT and SVR12, a CR was observed in 17
patients (77.3%) and in 14 patients (63.7%), respectively,
and a partial virologic plus clinical or immunological re-
sponse was seen in 4 patients (18.2%) and 5 patients
Fig. 1 Distribution of hepatitis C virus (HCV) RNA (a) and alanine transaminase (ALT) (b) levels in 22 HCV-positive patients with cryoglobulinaemia
treated with direct-acting antiviral agents at baseline, at week 4, at the end of treatment (EoT) and 12 weeks after treatment. SVR12 Sustained
virological response 12 weeks after therapy completion
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(22.7%), respectively. Also at the time of EoT and
SVR12, one patient (4.5%) and three patients (13.6%), re-
spectively, achieved only SVR. At SVR12, a CR was ob-
tained in 8 of 14 patients receiving SOF/RBV, in all 4
patients receiving SOF/LDV, and in 2 of the 3 patients
receiving 3D combo therapeutic regimens. At the same
time point, a PR was observed in 3 of the 14 patients re-
ceiving SOF/RBV, in the only patient receiving SOF/
DCV, and in 1 of the 3 patients receiving 3D combo.
Three of the fourteen patients who were given SOF/RBV
Fig. 2 Distribution of cryocrit levels (a), rheumatoid factor activity (b) and complement component C4 levels (c) in 22 hepatitis C virus-positive
patients with cryoglobulinaemia treated with direct-acting antiviral agents at baseline, at week 4, at the end of treatment (EoT) and 12 weeks
after treatment. SVR12 Sustained virological response 12 weeks after therapy completion
Table 2 Statistical analysis of the changes in the major biochemical parameters
Parameters Baseline End of treatment SVR12 Univariate analysis
Mean ± SD (range) Mean ± SD (range) p Value Mean ± SD (range) p Value p Value η2 Power
Cryocrit, % 1.8 ± 1.3 (0.5–4) 0.4 ± 0.6 (0–2) <0.0001 0.8 ± 1.4 (0–4.6) 0.001 <0.0001 0.470 0.999
Rheumatoid factor, IU/L 69.3 ± 119.1 (0–530) 30.9 ± 58.8 (0–255) 0.003 40.1 ± 63.0 (0–244) 0.083 0.002 0.281 0.913
C4, mg/dl 9.6 ± 7.3 (0–24) 13.6 ± 8.8 (4–36) 0.003 14.1 ± 9.4 (2–40) 0.002 0.001 0.313 0.962
ALT, IU/L 104.8 ± 144.7 (13–668) 20.9 ± 5.6 (12–32) <0.0001 21.1 ± 6.6 (8–32) <0.0001 <0.0001 0.572 1.000
Abbreviations: ALT Alanine transaminase, C4 Complement component C4, SVR12 Sustained virological response 12 weeks after therapy completion
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achieved SVR only. Given that all patients reached an
SVR 12 weeks after stopping therapy, 86.4% of patients
in our series obtained a clinical and/or immunological
benefit.
Comparing these results with those of our previous
study in which we assessed the response to pIFN-α +
RBV + RTX combination therapy [19], we found that the
all-oral therapeutic approach was significantly better in
terms of CR achievement (p = 0.0008 and p =0.030 at
EoT and SVR12, respectively) (Table 3).
All patients enrolled in the present study were kept
under follow-up, with the aim of assessing the persist-
ence of SVR and the possible changes of clinical and im-
munological features. At the time of this writing, 20
patients (90.9%) have achieved SVR24. Among them,
cryoglobulins reappeared in three patients (including the
patient with SLL), despite the persistence of SVR24 and
in the absence of clinical relapse. In one patient, the test
for cryoglobulins was negative at EoT, was positive again
at SVR12 and then disappeared at SVR24. So far, 6 of
the 14 CR patients at SVR12 have been followed for
48 weeks after completion of therapy and have main-
tained a CR. In two of them, cryoglobulins were absent,
although RF activity was still present at levels less than
baseline. In two additional patients, the cryocrit was
reduced at roughly 50% of basal value since EoT and
remained unchanged throughout follow-up. In the last
two patients, both cryocrit and RF remained undetect-
able. Moreover, one patient with PR and persistence of
symptomatic neuropathy despite undetectable cryoglo-
bulins and two SVR-only responsive patients with
symptomatic cryoglobulinaemia reached 48 weeks of
follow-up.
No severe adverse events related to the administration
of DAAs were observed. Two patients receiving SOF/RBV
developed progressive anaemia that required reduction
of the RBV dosage and erythropoietin administration.
Fatigue and mild pain of the dorsolumbar region were
Fig. 3 Cross-tab analysis and χ2 tests showing modifications of cryocrit, rheumatoid factor (RF), C4 and ALT levels in relation to antiviral therapy.
Besides hepatitis C virus RNA, cryocrit and ALT values were significantly influenced by therapy with respect to RF and C4 (p < 0.0001 and p < 0.0001,
respectively). ALT Alanine transaminase, C4 Complement component C4, EoT End of treatment, SVR12 Sustained virological response 12 weeks after
therapy completion
Table 3 Response rates in 22 patients with mixed cryoglobulinaemia following treatment with direct-acting antiviral agents at the





DAAs therapy, n (%)
EoT p Value Power SVR12 p Value Power
Complete 5 (33.3) 17 (77.3) 0.0008 0.895 14 (63.7) 0.030 0.867
Partial 5 (33.3) 4 (18.2) 0.216 0.801 5 (22.7) 0.553 0.895
SVR only 5 (33.3) 1 (4.5) 0.010 0.926 3 (13.6) 0.102 0.830
Abbreviations: DAA Direct-acting antiviral agent, EoT End of treatment, pIFN-α Pegylated interferon-α, RBV Ribavirin, SVR12 Sustained virological response 12 weeks
after therapy completion
Results achieved with pIFN-α/RBV regimen are given by comparison
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reported by several patients, but in none of them was
treatment discontinuation required.
Discussion
Following the identification of HCV as the largely preva-
lent etiologic agent of MC, researchers in several studies
have evaluated the therapeutic efficacy of antiviral drugs
such as pIFN-α, with or without RBV, in this condition
[14–16]. These studies consistently reported lower rates
of SVR in HCV-positive patients with than in those with-
out MC. In addition, IFN-based regimens were charac-
terised by severe adverse events, often leading to therapy
discontinuation. In consideration of the underlying B-cell
clonal expansion that characterises MC, B-cell depletion
therapy with RTX has also been employed after or in
addition to the antiviral treatment [17–19]. MC can indeed
be considered as an indolent, benign, lymphoproliferative
disease potentially susceptible of evolving into malignant
B-NHL [8].
The introduction into clinical practice of the new DAAs
for therapy of HCV infection offers for the first time the
possibility of achieving SVR in >90%, and virtually all, of
the chronically infected patients [21], with the coveted
perspective of viral eradication and clinical benefits also in
patients with extrahepatic manifestations of HCV infec-
tion such as MC.
In this study, we report a single-centre experience with
the use of the new DAAs in the therapy of HCV-related
MC. The first striking result to be emphasised is the
high rate of SVR12. All patients reached this primary
endpoint, a dramatic reduction of viraemia starting from
the fourth week of therapy. A slightly lower response
rate has been demonstrated in patients with MC than in
those obtained in patients without cryoglobulinaemia
with chronic HCV infection [24, 26]. The suboptimal ef-
ficacy of the SOF/RBV combination employed in those
studies has been considered as a possible factor account-
ing for the reduced SVR rates. At variance from these
observations, all seven of our patients with genotype 1
HCV infection who were treated with SOF/RBV regimen
reached SVR12. Gragnani et al. [26] similarly reported
100% SVR12 and SVR24 by using different SOF-based
antiviral combinations, confirming the very high antiviral
efficacy of these drugs. More recently, SVR12 was found
in 94% of 64 patients with MC treated with DAAs [27].
As reported above, at SVR12, cryoglobulins disappeared
or decreased by at least 50% in 77.3% of our patients,
whereas RF levels normalised in 50% and C4 in 63.6%
of the patients. Furthermore, statistical analysis (i.e.,
univariate analysis, cross-tabs and χ2 test) showed that
cryocrit and ALT levels were the biochemical parameters
more significantly influenced by therapy. Because ALT is a
biochemical marker of virus-induced hepatocytolysis, its
normalisation is obviously expected to follow viral load
reduction or disappearance. Similarly, because viral parti-
cles are constitutive components of the cryoprecipitating
immune complexes, the formation of such complexes is
clearly affected when viral particles are no longer present
following the administration of DAAs.
On one hand, RF and C4 levels are less influenced by
DAAs within the short period of 12 weeks after stopping
therapy and may represent independent markers not
only of clinical activity but also of persistently activated
B-cell clones. On the other hand, on the basis of our ex-
perience, variable changes of RF and C4 levels may
occur when a more prolonged follow-up is taken into
consideration, in step with either cryoglobulin disappear-
ance or recurrence.
The administration of DAAs was also shown to result
in a remarkable improvement of the clinical manifestations,
although symptoms persisted or worsened in six patients
(27.3%) despite their achievement of SVR12 or more. Even
so, the overall results (63.7% of CR plus 22.7% of PR) were
significantly better than those obtained with pIFN-α + RBV
therapy [19] or with a triple-combination therapy that
included first-generation protease inhibitors [20], with
the additional advantage of less frequent and less severe
side effects in patients receiving DAAs.
Sollima et al. [32] reported a clinical response at week
12 after treatment in two of seven HCV-positive pa-
tients with cryoglobulinaemia who were given all-oral
antiviral therapy, but one of them had relapsed vascu-
litis 8 weeks later. It can be inferred that in some cases
the pathogenetic process underlying MC progresses despite
viral clearance and that, when a “point of no return” has
been overstepped, the immune system keeps synthesising
pathogenic virus-independent immune complexes. At the
same time, when organ damage appears well established,
regression cannot be reasonably expected following anti-
viral therapy. In our study, only a partial benefit was ob-
served in patients with peripheral neuropathy. Renal
function worsened but did not reach end-stage renal dis-
ease in one patient with cryoglobulinaemic glomerulo-
nephritis, and vasculitic skin lesions persisted in another
patient.
At variance from previous studies in which researchers
reported NHL remission following antiviral therapy [33,
34], we observed disease progression in a patient with
SLL. Similar observations were reported by Gragnani et
al. [26] and more extensively by Arcaini et al. [35], who
studied 46 HCV-positive patients with indolent NHL
treated with IFN-free antiviral regimens and achieved
SVR12 in 98% of the patients and lymphoproliferative dis-
ease response of splenic marginal zone lymphomas in 73%
of the patients. On the contrary, NR was reported in pa-
tients with chronic lymphocytic leukaemia/SLL. Possible
explanations for these findings are that DAAs lack the
anti-proliferative and immunomodulatory effects of IFN-α
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and that chronic HCV infection has a different impact on
the oncogenic process in this particular subset of NHLs.
Interestingly, new clinical scenarios are being opened
following the treatment with DAAs of patients with
chronic HCV infection who have hematologic malignan-
cies [36]. In addition to preventing the development of
some NHLs, the use of DAAs in fact may avoid HCV re-
activation and hepatic flare after chemotherapy, may in-
duce a better outcome after allogeneic bone marrow
transplantation, and may reduce the risk of hepatic
failure due to cytotoxic drugs, especially in patients
with liver cirrhosis [36].
Conclusions
Although the worldwide experience with the use of
DAAs in HCV-positive patients with cryoglobulinaemia
is still limited, our single-centre study shows that vari-
able combinations of DAAs are able to induce SVR12
and SVR24 in virtually all patients. At 12 weeks after
EoT, CR and PR were diagnosed in as many as 86.4% of
the patients. These results not only are strikingly better
than those obtained with previous antiviral treatments
[14–16, 20, 37] but also are closely comparable, in terms
of SVR12, to the results reported in remarkably more
numerous multicentre cohorts of patients with chronic
HCV infection without MC [22, 23].
However, in step with the remarkably high rates of
virus eradication induced by the growing cluster of
DAAs, new and unforeseen scenarios are emerging. In a
minority of patients, clinical and immunological features
of cryoglobulinaemic vasculitis persist despite viral clear-
ance. The long-term evolution of these features is totally
unknown, and whether an early antiviral approach with
DAAs, before the occurrence of severe organ damage,
might be able to prevent the occurrence of these initially
virus-induced and then virus-cleared vasculitides remains
to be elucidated. In addition, at variance from patients
with MC achieving SVR and a successful vasculitic re-
sponse, in whom the regression of B-cell monoclonal
expansion in the bone marrow has been described [19],
the presence of circulating RF may be associated with
the over-representation of mature activated memory B
cells, which persist at least during the early phase fol-
lowing eradication of HCV [38]. To ascertain whether
an HCV-independent, B-cell lymphoproliferative disorder
may eventually appear in this particular group of pa-
tients, more prolonged follow-up after viral clearance is
necessary.
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